Does Cosentyx (secukinumab) worsen constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Cosentyx Worsen Constipation?

No, Cosentyx (secukinumab) does not worsen constipation and is not associated with constipation as an adverse effect. The documented adverse effects of secukinumab focus on infections, gastrointestinal inflammation, and other immune-related complications, but constipation is notably absent from the safety profile 1, 2, 3.

Documented Adverse Effects of Secukinumab

The most common adverse events associated with secukinumab include 1, 2:

  • Upper respiratory tract infections (very common, ≥1/10 patients)
  • Oral herpes
  • Headache
  • Rhinorrhea
  • Diarrhea (not constipation)
  • Nausea
  • Fatigue

Gastrointestinal Effects: The Real Concern

The primary gastrointestinal concern with secukinumab is inflammatory bowel disease (IBD), not constipation. Secukinumab has been associated with new-onset IBD or exacerbation of existing IBD 3, 4, 5, 6, 7:

  • New cases of Crohn's disease and ulcerative colitis have been reported during secukinumab treatment 4, 7
  • Lymphocytic colitis (a form of microscopic colitis characterized by diarrhea, not constipation) has been documented 5
  • Approximately 1% of patients treated with secukinumab developed new-onset IBD in one regional survey 6
  • Time to IBD onset ranges from 1 month to 5 years of exposure 6

Clinical Implications

If a patient on secukinumab experiences constipation, investigate alternative causes 1:

  • Review concomitant medications (opioids, anticholinergics, 5-HT3 antagonists, vinca alkaloids) 8
  • Assess for metabolic causes (hypercalcemia, hypokalemia, hypothyroidism) 8
  • Evaluate disease activity changes or lifestyle factors 1

Monitoring Recommendations

Focus monitoring on documented risks rather than constipation 2, 3:

  • Tuberculosis screening before initiation
  • Baseline and periodic complete blood counts for neutropenia
  • Clinical monitoring for signs of infection
  • Assessment for inflammatory bowel disease symptoms (diarrhea, abdominal pain, rectal bleeding) in patients with risk factors

Patients can be reassured that constipation is not an expected side effect of Cosentyx therapy 1.

References

Guideline

Cosentyx and Weight Gain

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Monitoring Recommendations for Patients on Cosentyx (Secukinumab)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hidradenitis Suppurativa Treatment with Secukinumab

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Secukinumab-Induced Lymphocytic Colitis.

Journal of investigative medicine high impact case reports, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.